Evidence map›Paper›PMID 41383045›Full record

ArticleOncoimmunology2025

Virus nanoparticle intratumoral vaccines for HER2

Miguel A Moreno-Gonzalez, Jessica Fernanda Affonso de Oliveira, Manuel L Penichet, Nicole F Steinmetz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miguel A Moreno-GonzalezAiiso Yufeng Li Family Department of Chemical and NanoEngineering, University of California, San Diego (UCSD), La Jolla, California, United States.ORCID 0000-0002-1601-9369
Jessica Fernanda Affonso de OliveiraAiiso Yufeng Li Family Department of Chemical and NanoEngineering, University of California, San Diego (UCSD), La Jolla, California, United States.ORCID 0000-0002-5474-2355
Manuel L PenichetDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States.ORCID 0000-0001-8788-2816
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and NanoEngineering, University of California, San Diego (UCSD), La Jolla, California, United States.ORCID 0000-0002-0130-0481

Funding

Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
NCI NIH HHS R01 CA253615
6 · The paper itself

Abstract

Our laboratory specializes in the intratumoral (i.t.) delivery of virus nanoparticles (VNPs) that activate immune cells and modulate the tumor microenvironment (TME). For this study, we conjugated the CH401 peptide-containing B-cell, helper T-cell, and cytotoxic T-cell epitopes of HER2-to the plant cowpea mosaic virus (CPMV) and bacteriophage Qβ to develop vaccines for HER2

Indexed as

Cancer VaccinesErb-b2 Receptor Tyrosine KinasesNanoparticlesNeoplasmsAnimalsCell Line, TumorComovirusEpitopes, T-LymphocyteFemaleHumansMiceMice, Inbred BALB CTumor MicroenvironmentCancer VaccinesEpitopes, T-LymphocyteERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesantibodiesCPMV (plant virus)HER2Immunotherapyintratumoral vaccineQβ (bacteriophage)Th1 bias

Identifiers

PMID41383045
PMCPMC12710919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.